



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/591,847

01/09/2007

Kenneth Hofland

BJS-620-454

3278

23117 7590 10/13/2010  
NIXON & VANDERHYE, PC  
901 NORTH GLEBE ROAD, 11TH FLOOR  
ARLINGTON, VA 22203

EXAMINER

KRISHNAN, GANAPATHY

ART UNIT

PAPER NUMBER

1623

MAIL DATE

DELIVERY MODE

10/13/2010

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.



The Examiner informed the Attorney of record that:

1. Cancel claims 6-10 since they are not tangible composition claims since the recited active agents cannot be made as a composition with radiation as one of the components.
2. In claim 1:
  - a) replace the terms, "which comprises" with "in the brain comprising".
  - b) at line 3, replace the term "topoisomerase-II poison" with "etoposide" or recite etoposide along with the other specific topoisomerase-II poisons recited at page 8, lines 14-18 using Markush language.
  - c) at line 3, instead of "bis-dioxypiperazine" recite the specific dioxypiperazine, namely dexrazoxane, recited in claim 3 and cancel claim 3.
  - d) at line 3, replace the term "wherein" with "and"
  - e) recite the dosage levels (stated at pages 9-10 of the specification) of all the active agents in claim 1 including the radiation.

The above amendments will put the application in a condition for allowance.

Mr. Sadoff said he will get back to the Examiner after talking to the inventors.